A PHASE 1B/2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OFKRT-232 IN PATIENTS WITH P53 WILD-TYPE (P53WT) MERKEL CELL CARCINOMA (MCC) WHO HAVE FAILED ANTI-PD-1 OR ANTI-PD-L1 IMMUNOTHERAPY, OR IN COMBINATION WITH AVELUMAB IN MCC PATIENTS WHO ARE ANTI-PD-1 OR ANTI-PD-L1 TREATMENT NAÏVE

Registry ID

KRT-232-103

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

KARTOS THERAPEUTICS INC

Start date

2022-08-24

Last update

2021-11-09

Conditions

• MERKEL CELL CARCINOMA

Related clinical trials

• A RANDOMIZED PHASE 2 STUDY OF ATR INHIBITION IN ADVANCED PD-(L)1-REFRACTORY MERKEL CELL CARCINOMA: THE MATRIX TRIAL
• A PHASE 3 OPEN-LABEL, SINGLE ARM STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PEMBROLIZUMAB (MK-3475) AS FIRST-LINE THERAPY IN PARTICIPANTS WITH ADVANCED MERKEL CELL CARCINOMA (KEYNOTE-913)

View on source registry